In Australia, although TGA approval exists for BRAFi, access to these medications for children and adults affected by BRAF-altered glioma relies on enrolment into clinical trials, company-specific Managed Access Programs, hospital-specific drug usage committees, and through private funding, particularly in the AYA and adult setting. The gene discussed is BRAF; the disease is glioma.